ImmunoPrecise Antibodies Sees Unusually High Options Volume (NASDAQ:IPA)

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 3,524 call options on the stock. This is an increase of 6,193% compared to the typical volume of 56 call options.

Analyst Ratings Changes

Separately, HC Wainwright reduced their target price on shares of ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC raised its stake in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 63,910 shares of the company’s stock after buying an additional 26,310 shares during the quarter. Renaissance Technologies LLC owned 0.24% of ImmunoPrecise Antibodies worth $65,000 at the end of the most recent reporting period. Institutional investors own 6.70% of the company’s stock.

ImmunoPrecise Antibodies Price Performance

IPA opened at $0.60 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.85 and a current ratio of 1.01. ImmunoPrecise Antibodies has a 1-year low of $0.32 and a 1-year high of $2.60. The company has a 50-day moving average of $0.44 and a 200-day moving average of $0.60. The company has a market capitalization of $18.64 million, a P/E ratio of -0.77 and a beta of 0.01.

ImmunoPrecise Antibodies (NASDAQ:IPA) last posted its earnings results on Tuesday, December 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%. Equities analysts expect that ImmunoPrecise Antibodies will post -0.27 EPS for the current fiscal year.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.